The report will be securely delivered to the provider who ordered the test, either via secure fax or secure email.

The miR Sentinel™ Prostate Cancer Test is commercially available in most U.S. states as well as Puerto Rico. The test is not currently available in New York.

miR Sentinel has CPT PLA code 0424U and is listed on the 2026 Medicare Clinical Laboratory Fee Schedule. Broad coverage policies with private payers remain in build. MiRNA Scientific submits claims and pursues appeals on the patient's behalf. For Medicare beneficiaries: if a Medicare claim is denied, MiRNA Scientific does not bill the patient for any remaining balance. For other patients with out-of-pocket exposure, the miR Access patient-assistance program caps household out-of-pocket cost on a sliding scale based on income, with payment-over-time available. Almost all patients pay no more than approximately $250 for the test.

miR's Sentinel™ Prostate Cancer Test is currently only available through a healthcare provider. Please speak with your physician about possible testing options.